Drug Trial Radar · NCT06901505
To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
353
Actual
Start
Jul 24, 2025
Primary completion
Aug 12, 2026
Study completion Aug 12, 2026
Sponsor
- Lead sponsor
- Akebia TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Mar 30, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, randomized (1:1), open-label, active-controlled, pragmatic study of the efficacy of vadadustat administered three times a week compared to standard of care erythropoiesis-stimulating agent for the treatment of anemia in in-center hemodialysis participants with end-stage kidney disease (ESKD). A subset of sites will participate in a red blood cell (RBC) sub-study where changes in the phenotype of RBCs in response to vadadustat treatment relative to methoxy polyethylene glycol-epoetin beta treatment in DD-CKD participants with anemia will be assessed. A separate informed consent form (ICF) will be signed by these participants who opt to be in the RBC sub-study. Of the 350 participants in the main study, approximately 28 participants will also be enrolled into the RBC sub-study. The total duration of the study is approximately 35 Weeks including screening and follow-up.
Conditions
- Anemia of Chronic Kidney Disease
Interventions
Erythropoiesis-Stimulating Agent (ESA)Drug
Administered by intra-venous (IV) infusion.
VadadustatDrug
300mg, oral tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in hemoglobin (Hb)Time frame: Baseline and the mean of Week 20 to 24
Locations
18 sites in 1 country. Site status is shown where the registry gives one.
DaVita Research Site
Montgomery, Alabama
DaVita Research Site
Hartford, Connecticut
DaVita Research Site
Middlebury, Connecticut
DaVita Research Site
Columbus, Georgia
DaVita Research Site #1
Minneapolis, Minnesota
DaVita Research Site
Minneapolis, Minnesota
DaVita Research Site
Henderson, Nevada
DaVita Research Site
Las Vegas, Nevada
DaVita Research Site #1
El Paso, Texas
DaVita Research Site
El Paso, Texas
DaVita Research Site #1
Houston, Texas
DaVita Research Site
Houston, Texas
DaVita Research Site #1
San Antonio, Texas
DaVita Research Site #2
San Antonio, Texas
DaVita Research Site
San Antonio, Texas
DaVita Research Site
The Woodlands, Texas
DaVita Research Site #1
Norfolk, Virginia
DaVita Research Site
Norfolk, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.